02:43 AM EDT, 10/27/2026 (MT Newswires) -- Basilea Pharmaceutica (BSLN.SW) on Tuesday raised its full-year 2026 outlook. The Swiss-listed biopharmaceutical company now expects a 123% jump in its 2026 operating profit to 115 million francs from 51.5 million francs a year ago. The previous guidance was for a 40% increase The company forecasts its revenue to increase 33% to 310 million francs from 232.4 million francs a year earlier. Previously, it projected a 15% increase in revenue.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.